OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis.
II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.

Start Date01 Sep 1997

Sponsor / Collaborator

SciClone Pharmaceuticals LLC

100 Clinical Results associated with PD-116948

100 Translational Medicine associated with PD-116948

100 Patents (Medical) associated with PD-116948

1,957

Literatures (Medical) associated with PD-116948

01 Jun 2025·Chemico-Biological Interactions

Enhancing cardiac safety: Liposomal ciprofloxacin mitigates anthracycline-induced cardiotoxicity without compromising anticancer efficacy

Article

Author: Swiech, Olga ; Boguszewska-Czubara, Anna

Anthracyclines, such as doxorubicin and epirubicin (EPI), are integral in the treatment of solid tumors and hematological malignancies but are associated with cardiotoxicity, potentially leading to heart failure. The underlying mechanisms involve the generation of reactive oxygen species (ROS), alterations in iron metabolism, and the inhibition of topoisomerase 2β (Top2β), resulting in mitochondrial dysfunction and cell death. Fluoroquinolones, including ciprofloxacin (CPX), enhance the efficacy of anthracyclines by inhibiting topoisomerase II and inducing apoptosis, thereby indicating a promising combination therapy. This study investigated the impact of environmental pH on the cardiotoxicity and myocardial accumulation of anthracyclines, as well as the cardioprotective and synergistic potential of CPX when co-administered with epirubicin. The findings revealed that only the zwitterionic form of CPX, either free or encapsulated in liposomes, offers significant cardioprotection without compromising the anticancer activity of EPI. Remarkably, the combination of liposomal CPX and EPI completely attenuates EPI's cardiotoxicity. These results suggest that initiating treatment with liposomal CPX prior to EPI administration may optimize cardioprotection while maintaining therapeutic efficacy against cancer.

01 May 2025·Ultrasonics Sonochemistry

Non-porous silica nanoparticles as a cavitation sensitive vehicle for antibiotic delivery

Article

Author: Walmsley, Anthony Damien ; Lucas, Margaret ; Prentice, Paul ; Pikramenou, Zoe ; Jacobson, Ben ; Stevenson, Jack ; Ball, Grace ; Boroujeni, Faraz Amini ; Kuehne, Sarah A

Ultrasound stimulated drug delivery is attractive for controlled dose and localised delivery to reduce excess loss of drug and side effects, which for antibiotics is pertinent to the fight against antimicrobial resistance. Low frequency ultrasound is commonly used in dental clinical practice for bacterial biofilm removal and is an attractive versatile stimulus for drug release. Here we introduce nonporous (amorphous) silica nanoparticles as a biocompatible, encapsulant for triggered drug release by low frequency ultrasound. A 20 kHz ultrasonic sonotrode is used in to evaluate the release of the antibiotic ciprofloxacin, CPX, from non-porous particles, CPX ⊂ SiO₂. Laser doppler vibrometry (LDV) was employed to characterise the ultrasonic vibration displacement of the sonotrode. Drug release from CPX ⊂ SiO₂ was monitored for increasing the tip displacement. Clinically relevant quantities of CPX release (5.7 mg/L) occurred at 40 μm tip displacement in our studies. A strong correlation was observed between cavitation features in the acoustic spectra and drug release from CPX ⊂ SiO₂. Silica nanoparticles with and without encapsulated CPX, CPX ⊂ SiO₂ and SiO₂, respectively, were found to promote cavitation at lower amplitudes confirmed by high-speed imaging, in contrast to mesoporous particles with and without adsorbed CPX, CPX@m-SiO₂ and m-SiO₂. Spectra of the emissions collected via an acoustic cavitation detector supported these results. Our studies demonstrate a novel platform for drug delivery employing low frequency ultrasound for synergistic enhancement of cavitation effects and triggered drug release.

16 Apr 2025·Environmental Technology

Theoretical and experimental studies of cephalexin adsorption on aluminium as a new alternative of removal from wastewater

Article

Author: Moeller-Chávez, Gabriela Eleonora ; Sánchez-Ponce, Angélica ; Bustos-Terrones, Victoria ; López-Aguilar, Samantha Giselle ; Uruchurtu-Chavarín, Jorge ; Díaz-Cárdenas, María Yesenia

Cephalexin (CPX) is an antibiotic widely used to treat many infections. CPX has become an emerging pollutant present in wastewater. On the other hand, it is well known that organic compounds can be adsorbed over metal surfaces when the metal is in active state such as when it is rusting. This work proposes an alternative for the elimination of CPX from wastewater, applying electrochemical principles using a conventional and cheap substrate, aluminium. The first part consisted of obtaining the active states of aluminium electrodes carrying out voltametric curves at different pH (4, 7 and 9) to find the particular condition of interaction between CPX and metal surface. The potential was used in the potentiostatic tests to set the activation potential of metal at different times. After the treatment, electrolyte solutions were analysed using UV-vis spectra, and the aluminium surfaces were studied by optical micrographs and X-ray diffraction. In addition, aluminium-CPX interactions were corroborated by quantum-chemical calculations and adsorption isotherms. All results indicate that it was possible for the CPX removal at basic pH conditions, where the molecule adsorption on the aluminium substrate occurs due to a strong electrostatic interaction.

100 Deals associated with PD-116948

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12946

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystic Fibrosis	Phase 2	United States	SciClone Pharmaceuticals LLC	-
Cystic Fibrosis	Phase 2	-	National Institutes of Health	-
Cystic Fibrosis	Phase 2	-	National Institutes of Health	-
Cystic Fibrosis	Phase 2	United States	SciClone Pharmaceuticals LLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SFN2009	Not Applicable	Neuromuscular Junction Diseases	-	DPCPX	cfyrbkazqk(bojshjfxsn) = zesajdpxuy fxswpxhhks (qnfeucfiyv )	-	19 Oct 2009
IEC2009	Not Applicable	Hyperthermia	-	Aminophylline 10mg/kg	qtxxbkukre(iybvbquitp) = uvkbeqvylg hqcmftonrr (hwvgnuscwm ) View more	-	02 Jul 2009
				Aminophylline 25mg/kg	qtxxbkukre(iybvbquitp) = tlsmtkoyuj hqcmftonrr (hwvgnuscwm ) View more
SFN2008	Not Applicable	-	-	Caffeine	cskmzgozgo(dsucqokboj) = bvtpfughwz ruuyozjpre (sbyhipwrov )	-	18 Nov 2008
				DPCPX	cskmzgozgo(dsucqokboj) = irxmuhfbdo ruuyozjpre (sbyhipwrov )
SFN2006	Not Applicable	-	-	Caffeine	dbeisuzjag(dxtadjacvs) = hyifxdbbyl dyjbsyeinx (bhqavrenhr ) View more	-	17 Oct 2006
				DPCPX	dbeisuzjag(dxtadjacvs) = fovbehweka dyjbsyeinx (bhqavrenhr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PD-116948

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation